Posted by Michael Wonder on 25 Jan 2017
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
25 January 2017 - NICE published guidance that recommended ibrutinib for chronic lymphocytic leukaemia in adults who have had at least one previous treatment or have a 17p deletion or TP53 mutation and for whom chemoimmunotherapy is unsuitable.
The guidance applies only when the company Janssen provides ibrutinib with the discount agreed in the patient access scheme.
